{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:09Z","timestamp":1791389169267,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["INTO-PROT grant #12092"],"award-info":[{"award-number":["INTO-PROT grant #12092"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Distinguishing pseudoprogression (PsP) from true progression (TP) in glioblastoma (GBM) remains a diagnostic challenge, yet is essential for guiding treatment and counseling prognosis. This study retrospectively assessed the incidence, clinical predictors, and survival impact of PsP compared to TP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with surgically treated GBM and postoperative (chemo)radiotherapy in two Dutch hospitals (2006\u20132021) were included. Reports of magnetic resonance imaging (MRI) scans performed 4 months post-radiotherapy and at 3-month intervals, as well as reports of MRI scans prompted by neurological decline, were evaluated for PsP, TP, or mixed response (MR). Associations with clinical, tumor, and treatment characteristics and overall survival (OS) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 424 GBM patients, 175 were eligible for PsP analysis. The incidence of PsP was 29.1%, and PsP was associated with longer OS (median 16.6 months, 95% CI 12.0\u201321.2) compared to MR (14.1 months, 95% CI 11.1\u201317.2) and TP (11.6 months, 95% CI 10.0\u201313.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010). However, PsP occurring\u2009&lt;\u20094 months after chemoradiotherapy was linked to shorter OS (11.3 months) than PsP\u2009&gt;\u20094 months (17.4 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027). Male sex was significantly associated with outcome in univariate analysis, showing a trend toward significance in multivariate analysis. Treatment completion remained significant only in the multivariate model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PsP is associated with improved survival compared to TP, though early-onset PsP portends poorer outcomes. None of the evaluated factors were a significant predictor of PsP in both univariate and multivariate analyses. Future research should focus on validating molecular markers, and refining PsP definitions using standardized criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05299-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:56:12Z","timestamp":1761314172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis"],"prefix":"10.1007","volume":"176","author":[{"given":"L. J. N.","family":"Hoosemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9137-5728","authenticated-orcid":false,"given":"L. F.","family":"Panayotopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2796-729X","authenticated-orcid":false,"given":"S. M. J.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-8494","authenticated-orcid":false,"given":"M.","family":"Verduin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. M. E.","family":"Anten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C. O. S.","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6187-572X","authenticated-orcid":false,"given":"S. M. H.","family":"Huijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-8938","authenticated-orcid":false,"given":"S. R.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-0692","authenticated-orcid":false,"given":"F. W. P. J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8955-8702","authenticated-orcid":false,"given":"L. C.","family":"Steggink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-3420","authenticated-orcid":false,"given":"L.","family":"Ackermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-0728","authenticated-orcid":false,"given":"O. E. M. G.","family":"Schijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9416-5830","authenticated-orcid":false,"given":"O. P. M.","family":"Teernstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-8189","authenticated-orcid":false,"given":"K.","family":"Hovinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8894-6230","authenticated-orcid":false,"given":"J. C.","family":"Beckervordersandforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-1565","authenticated-orcid":false,"given":"I.","family":"Compter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6279","authenticated-orcid":false,"given":"D. B. P.","family":"Eekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1386-3027","authenticated-orcid":false,"given":"M. A.","family":"Vooijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-2202","authenticated-orcid":false,"given":"M. P. G.","family":"Broen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0155-3005","authenticated-orcid":false,"given":"A.","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"5299_CR1","doi-asserted-by":"publisher","first-page":"n1560","DOI":"10.1136\/bmj.n1560","volume":"374","author":"C McKinnon","year":"2021","unstructured":"McKinnon C, Nandhabalan M, Murray SA, Plaha P (2021) Glioblastoma: clinical presentation, diagnosis, and management. BMJ 374:n1560","journal-title":"BMJ"},{"issue":"10","key":"5299_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"11","key":"5299_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C et al (2017) Short-Course radiation plus Temozolomide in elderly patients with glioblastoma. N Engl J Med 376(11):1027\u20131037","journal-title":"N Engl J Med"},{"issue":"9","key":"5299_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstrom","year":"2012","unstructured":"Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol 13(9):916\u2013926","journal-title":"Lancet Oncol"},{"issue":"7","key":"5299_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant Astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707\u2013715","journal-title":"Lancet Oncol"},{"issue":"5","key":"5299_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3171\/2022.8.JNS221068","volume":"138","author":"F Laigle-Donadey","year":"2023","unstructured":"Laigle-Donadey F, Metellus P, Guyotat J, Menei P, Proust F, Dufour H et al (2023) Surgery for glioblastomas in the elderly: an association des Neuro-oncologues d\u2019expression Francaise (ANOCEF) trial. J Neurosurg 138(5):1199\u20131205","journal-title":"J Neurosurg"},{"issue":"5","key":"5299_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453\u2013461","journal-title":"Lancet Oncol"},{"issue":"1","key":"5299_CR8","first-page":"36","volume":"11","author":"H Blakstad","year":"2024","unstructured":"Blakstad H, Mendoza Mireles EE, Heggebo LC, Magelssen H, Sprauten M, Johannesen TB et al (2024) Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study. Neurooncol Pract 11(1):36\u201345","journal-title":"Neurooncol Pract"},{"issue":"4","key":"5299_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3892\/ijo.2011.1260","volume":"40","author":"HB Pouleau","year":"2012","unstructured":"Pouleau HB, Sadeghi N, Baleriaux D, Melot C, De Witte O, Lefranc F (2012) High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40(4):923\u2013928","journal-title":"Int J Oncol"},{"issue":"12","key":"5299_CR10","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1002\/cam4.1242","volume":"6","author":"C Balana","year":"2017","unstructured":"Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S et al (2017) Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Med 6(12):2858\u20132866","journal-title":"Cancer Med"},{"issue":"1","key":"5299_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0317167100009628","volume":"37","author":"P Sanghera","year":"2010","unstructured":"Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36\u201342","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"5299_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00062-017-0584-x","volume":"28","author":"AW Abbasi","year":"2018","unstructured":"Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A (2018) Incidence of tumour progression and pseudoprogression in High-Grade gliomas: a systematic review and Meta-Analysis. Clin Neuroradiol 28(3):401\u2013411","journal-title":"Clin Neuroradiol"},{"issue":"11","key":"5299_CR13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"1","key":"5299_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3174\/ajnr.A6358","volume":"41","author":"DJ Leao","year":"2020","unstructured":"Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B (2020) Response assessment in Neuro-Oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol 41(1):10\u201320","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"5299_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/ene.12192","volume":"20","author":"E Van Mieghem","year":"2013","unstructured":"Van Mieghem E, Wozniak A, Geussens Y, Menten J, De Vleeschouwer S, Van Calenbergh F et al (2013) Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 20(10):1335\u20131341","journal-title":"Eur J Neurol"},{"issue":"11","key":"5299_CR16","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz Jr","year":"2011","unstructured":"Hygino da Cruz LC Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978\u20131985","journal-title":"AJNR Am J Neuroradiol"},{"key":"5299_CR17","doi-asserted-by":"publisher","first-page":"6828396","DOI":"10.1155\/2018\/6828396","volume":"2018","author":"A Zikou","year":"2018","unstructured":"Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI (2018) Radiation Necrosis, Pseudoprogression, Pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging 2018:6828396","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"5299_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-010-0305-7","volume":"102","author":"HC Kang","year":"2011","unstructured":"Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim JH et al (2011) Pseudoprogression in patients with malignant gliomas treated with concurrent Temozolomide and radiotherapy: potential role of p53. J Neurooncol 102(1):157\u2013162","journal-title":"J Neurooncol"},{"issue":"6","key":"5299_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/cns.14.42","volume":"3","author":"S Gahramanov","year":"2014","unstructured":"Gahramanov S, Varallyay C, Tyson RM, Lacy C, Fu R, Netto JP et al (2014) Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme May predict improved survival. CNS Oncol 3(6):389\u2013400","journal-title":"CNS Oncol"},{"issue":"1","key":"5299_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11060-018-2855-z","volume":"139","author":"LS Rowe","year":"2018","unstructured":"Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H et al (2018) Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. J Neurooncol 139(1):145\u2013152","journal-title":"J Neurooncol"},{"issue":"2","key":"5299_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307\u2013320","journal-title":"Neurotherapeutics"},{"issue":"1","key":"5299_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clinimag.2012.02.016","volume":"37","author":"RJ Young","year":"2013","unstructured":"Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z et al (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37(1):41\u201349","journal-title":"Clin Imaging"},{"issue":"13","key":"5299_CR23","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192\u20132197","journal-title":"J Clin Oncol"},{"key":"5299_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clineuro.2016.10.004","volume":"151","author":"H Li","year":"2016","unstructured":"Li H, Li J, Cheng G, Zhang J, Li X (2016) IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg 151:31\u201336","journal-title":"Clin Neurol Neurosurg"},{"key":"5299_CR25","doi-asserted-by":"publisher","first-page":"627325","DOI":"10.3389\/fonc.2021.627325","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Ren X, Dong G, Wang J, Jiang H, Yang C et al (2021) Distinguishing pseudoprogression from true early progression in isocitrate dehydrogenase Wild-Type glioblastoma by interrogating Clinical, Radiological, and molecular features. Front Oncol 11:627325","journal-title":"Front Oncol"},{"issue":"3","key":"5299_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11060-022-04088-3","volume":"159","author":"A Hagiwara","year":"2022","unstructured":"Hagiwara A, Schlossman J, Shabani S, Raymond C, Tatekawa H, Abrey LE et al (2022) Incidence, molecular characteristics, and imaging features of clinically-defined pseudoprogression in newly diagnosed glioblastoma treated with chemoradiation. J Neurooncol 159(3):509\u2013518","journal-title":"J Neurooncol"},{"issue":"2","key":"5299_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10014-012-0109-x","volume":"30","author":"H Motegi","year":"2013","unstructured":"Motegi H, Kamoshima Y, Terasaka S, Kobayashi H, Yamaguchi S, Tanino M et al (2013) IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with Temozolomide and radiotherapy. Brain Tumor Pathol 30(2):67\u201372","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"5299_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12885-021-08004-2","volume":"21","author":"J Xi","year":"2021","unstructured":"Xi J, Hassan B, Katumba RGN, Khaddour K, Govindan A, Luo J et al (2021) The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. BMC Cancer 21(1):285","journal-title":"BMC Cancer"},{"issue":"34","key":"5299_CR29","doi-asserted-by":"publisher","first-page":"55377","DOI":"10.18632\/oncotarget.10553","volume":"7","author":"X Qian","year":"2016","unstructured":"Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M et al (2016) Identification of biomarkers for Pseudo and true progression of GBM based on radiogenomics study. Oncotarget 7(34):55377\u201355394","journal-title":"Oncotarget"},{"issue":"8","key":"5299_CR30","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"3","key":"5299_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jmri.26171","volume":"48","author":"SC Thust","year":"2018","unstructured":"Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging 48(3):571\u2013589","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"5299_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/neuonc\/now148","volume":"19","author":"P Patel","year":"2017","unstructured":"Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol 19(1):118\u2013127","journal-title":"Neuro Oncol"},{"issue":"11","key":"5299_CR33","doi-asserted-by":"publisher","first-page":"e6333","DOI":"10.1097\/MD.0000000000006333","volume":"96","author":"B Wan","year":"2017","unstructured":"Wan B, Wang S, Tu M, Wu B, Han P, Xu H (2017) The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: A meta-analysis. Med (Baltim) 96(11):e6333","journal-title":"Med (Baltim)"},{"issue":"1","key":"5299_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/neuonc\/nou129","volume":"17","author":"A Radbruch","year":"2015","unstructured":"Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Baumer P et al (2015) Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol 17(1):151\u2013159","journal-title":"Neuro Oncol"},{"issue":"4","key":"5299_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jgo.2019.08.014","volume":"11","author":"E Burton","year":"2020","unstructured":"Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S (2020) Failure to complete standard radiation therapy in glioblastoma patients: patterns from a National database with implications for survival and therapeutic decision making in older glioblastoma patients. J Geriatr Oncol 11(4):680\u2013687","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"5299_CR36","first-page":"vdac128","volume":"4","author":"ME El-Abtah","year":"2022","unstructured":"El-Abtah ME, Talati P, Fu M, Chun B, Clark P, Peters A et al (2022) Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma. Neurooncol Adv 4(1):vdac128","journal-title":"Neurooncol Adv"},{"issue":"2","key":"5299_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cncr.23562","volume":"113","author":"W Taal","year":"2008","unstructured":"Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with Temozolomide. Cancer 113(2):405\u2013410","journal-title":"Cancer"},{"key":"5299_CR38","doi-asserted-by":"publisher","first-page":"103188","DOI":"10.1016\/j.critrevonc.2020.103188","volume":"157","author":"C Le Fevre","year":"2021","unstructured":"Le Fevre C, Lhermitte B, Ahle G, Chambrelant I, Cebula H, Antoni D et al (2021) Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: part 1 - Molecular, morphological and clinical features. Crit Rev Oncol Hematol 157:103188","journal-title":"Crit Rev Oncol Hematol"},{"key":"5299_CR39","doi-asserted-by":"publisher","first-page":"110936","DOI":"10.1016\/j.radonc.2025.110936","volume":"208","author":"L Lauwens","year":"2025","unstructured":"Lauwens L, Ribeiro MF, Zegers CML, Hoyer M, Alapetite C, Blomstrand M et al (2025) Systematic review of MRI alterations in the brain following proton and photon radiation therapy: towards a uniform European particle therapy network (EPTN) definition. Radiother Oncol 208:110936","journal-title":"Radiother Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05299-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:35:23Z","timestamp":1767702923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5299"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05299-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective cohort study, approved by the Maastricht Academic Hospital Ethical committee (METC 16-4-022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}